bone-related

By Targets:	Apoptosis (2) c-Fms (1) Caspase (1) HIF/HIF Prolyl-Hydroxylase (1) Isotope-Labeled Compounds (1) NF-κB (2) RANKL/RANK (2) Src (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Endocrinology (2) Inflammation/Immunology (1) Neurological Disease (1)

Targets Recommended: Interleukin Related Oxysterol-binding Protein-related Protein (ORP) Mas-related G-protein-coupled Receptor (MRGPR) Trk Receptor ROR NEKs Kallikrein Atg4 CGRP Receptor RUNX Atg8/LC3 Arp2/3 Complex ATM/ATR sFRP-1 CD44 Neuropeptide S Receptor Cdc42-binding kinase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9958

Denosumab 1 Publications Verification AMG-162	NF-κB Caspase Apoptosis RANKL/RANK	Endocrinology Cancer
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .

HY-P9958A

Denosumab (anti-TNFSF11) 1 Publications Verification	RANKL/RANK Apoptosis NF-κB	Neurological Disease Endocrinology Cancer
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .

HY-136362

ARRY-382	c-Fms	Inflammation/Immunology Cancer
ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC₅₀ of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers .

HY-125064

AP22408	Src	Cancer
AP22408 is a nonpeptide inhibitor against Src SH2 with an IC₅₀ value of 0.3 μM. AP22408 inhibits rabbit osteoclast-mediated resorption of dentine, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model. AP22408 is proming for rasearch of osteoporosis and other bone-related diseases such as Paget’s disease, osteolytic bone metastasis and hypercalcemia associated with malignancy .

HY-15893G

DMOG Dimethyloxallyl Glycine	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease
DMOG (GMP) is the GMP level of DMOG (HY-15893). DMOG (GMP) is a HIF-1α stabilizer. DMOG (GMP) promotes the osteogenic, angiogenic, and chondrogenic differentiation of stem cells by stabilizing the expression of HIF-1α. DMOG (GMP) can enhance the osteogenic and angiogenic differentiation potential of stem cells, thereby improving bone regeneration in bone defects. DMOG (GMP) can be used in the research of bone defect repair, vascularized bone regeneration, and the treatment of bone-related diseases (such as osteoporosis and femoral head necrosis) .

HY-176347S

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2	Isotope-Labeled Compounds	Cancer
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

Cat. No.	Product Name	Type

HY-15893G

DMOG (GMP) Dimethyloxallyl Glycine (GMP)	Fluorescent Dye
DMOG (GMP) is the GMP level of DMOG (HY-15893). DMOG (GMP) is a HIF-1α stabilizer. DMOG (GMP) promotes the osteogenic, angiogenic, and chondrogenic differentiation of stem cells by stabilizing the expression of HIF-1α. DMOG (GMP) can enhance the osteogenic and angiogenic differentiation potential of stem cells, thereby improving bone regeneration in bone defects. DMOG (GMP) can be used in the research of bone defect repair, vascularized bone regeneration, and the treatment of bone-related diseases (such as osteoporosis and femoral head necrosis) .

DMOG (GMP)

Dimethyloxallyl Glycine (GMP)

Fluorescent Dye

DMOG (GMP) is the GMP level of DMOG (HY-15893). DMOG (GMP) is a HIF-1α stabilizer. DMOG (GMP) promotes the osteogenic, angiogenic, and chondrogenic differentiation of stem cells by stabilizing the expression of HIF-1α. DMOG (GMP) can enhance the osteogenic and angiogenic differentiation potential of stem cells, thereby improving bone regeneration in bone defects. DMOG (GMP) can be used in the research of bone defect repair, vascularized bone regeneration, and the treatment of bone-related diseases (such as osteoporosis and femoral head necrosis) .

Cat. No.	Product Name	Type

HY-15893G

DMOG (GMP) Dimethyloxallyl Glycine (GMP)	Biochemical Assay Reagents
DMOG (GMP) is the GMP level of DMOG (HY-15893). DMOG (GMP) is a HIF-1α stabilizer. DMOG (GMP) promotes the osteogenic, angiogenic, and chondrogenic differentiation of stem cells by stabilizing the expression of HIF-1α. DMOG (GMP) can enhance the osteogenic and angiogenic differentiation potential of stem cells, thereby improving bone regeneration in bone defects. DMOG (GMP) can be used in the research of bone defect repair, vascularized bone regeneration, and the treatment of bone-related diseases (such as osteoporosis and femoral head necrosis) .

DMOG (GMP)

Dimethyloxallyl Glycine (GMP)

Biochemical Assay Reagents

DMOG (GMP) is the GMP level of DMOG (HY-15893). DMOG (GMP) is a HIF-1α stabilizer. DMOG (GMP) promotes the osteogenic, angiogenic, and chondrogenic differentiation of stem cells by stabilizing the expression of HIF-1α. DMOG (GMP) can enhance the osteogenic and angiogenic differentiation potential of stem cells, thereby improving bone regeneration in bone defects. DMOG (GMP) can be used in the research of bone defect repair, vascularized bone regeneration, and the treatment of bone-related diseases (such as osteoporosis and femoral head necrosis) .

Cat. No.	Product Name	Target	Research Area

HY-P9958

Denosumab 1 Publications Verification AMG-162	NF-κB Caspase Apoptosis RANKL/RANK	Endocrinology Cancer
Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .

HY-P9958A

Denosumab (anti-TNFSF11) 1 Publications Verification	RANKL/RANK Apoptosis NF-κB	Neurological Disease Endocrinology Cancer
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .

Cat. No.	Product Name	Chemical Structure

HY-176347S

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.